Welcome to VolitionRx Ltd's second quarter 2026 earnings conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be open for questions. If you have a question, please press the star key, followed by the number one on your touch tone phone. If you would like to withdraw your question, please press the star key followed by the number two. If you're using speaker equipment, please lift the handset before making your selections. This conference call is being recorded today, August 14th, 2026. I'd now like to turn the conference call over to Louise Batchelor, Group Chief Marketing and Communications Officer. Please go ahead. Welcome everyone to today's earnings conference call for VolitionRx Limited. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance, or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any forward-looking statements made during the course of this call. Cameron Reynolds, Group Chief Executive Officer, will open the call, providing a summary of key recent achievements, and will then hand over to Terig Hughes, Group Chief Financial Officer, to give a financial report. Before returning to Cameron, who will discuss upcoming milestones. We will then open the conference call to a question and answer session. With that, I'll turn the call over to Cameron. Thanks, Lou, and thank you everyone for joining Volition's earnings call today. As always, we very much appreciate your time, given the busy earnings season. We have made strong progress across all our product pillars so far in 2026. Taking each in turn, first starting with Nu.Q NETs. Subsequent to quarter end, we issued a comprehensive video update and PDF showcasing the significant scientific and clinical evidence we have amassed relating to our Nu.Q NETs products and listing the extensive base of data now published. Results have consistently demonstrated that our Nu.Q NETs H3.1 assay accurately distinguishes sepsis from non-infectious systemic inflammation, is highly correlated with disease severity, and provides excellent prognostic utility for outcomes such as organ failure and mortality. Moreover, Nu.Q NETs provides new and additional information above standard organ failure scores such as APACHE II and SOFA scores. Professor Djillali Annane, one of the world's leading experts in sepsis, has stated that he believes Nu.Q NETs could become a game changer in modifying a patient's trajectory, and that introducing Nu.Q NETs into hospitals would lead to new ways of treating sepsis, improving patient survival, and the quality of life of survivors. A very powerful testament indeed. Excitingly for Nu.Q NETs, we have also made incredible progress in the development and evaluation of our lateral flow prototype assay. A little over a year ago, in July of 2025, we announced the quantification of nucleosomes in whole venous blood using our lateral flow prototype assay. Then, in April of this year, we reported the technical breakthrough of being able to detect nucleosomes in capillary blood or blood from a finger prick. Now fast-forward to earlier this week and our announcement that we have demonstrated correlation of the lateral flow prototype assay and our established CE-marked automated Nu.Q NETs assay in samples of critically ill confirmed sepsis patients in the intensive care unit. The ability to rapidly identify high-risk patients at the point of care by quantifying their nucleosome levels using a finger- prick sample and simple lateral flow device aims to enable quicker clinical decision-making and consequently, better patient outcomes. This prototype technology has the exciting potential to strengthen our product portfolio. With recent estimates indicating approximately 166 million cases of sepsis worldwide, the potential addressable market is absolutely huge. All caused sepsis-related deaths in 2021 represented 31.5% of total global deaths, with the highest burden of mortality in lower and middle-income countries. This is a potential game changer, not only in diseases where time is critical, such as sepsis, but also in significantly expanding potential use cases beyond traditional hospital infrastructure. It also creates a compelling pathway into underserved lower-income countries, where laboratory infrastructure may be weak or nonexistent. By enabling decentralized testing, our total addressable market expands. More on which later when I discuss upcoming milestones. We have made and continue to make incredibly rapid progress in the development and evaluation of this finger- prick technology. Outside of sepsis, but still with Nu.Q NETs, and diseases associated with NETosis, we were delighted this quarter to announce our collaboration with Sysmex Corporation, a multibillion-dollar market capitalization company listed on the Tokyo Stock Exchange. Sysmex is a global leader in the field of in vitro diagnostics for hemostasis and thrombosis, among other diseases, where neutrophil extracellular traps, NETs, play such an important role. We have already successfully transferred our Nu.Q NETs assay onto Sysmex's platform, and we are delighted they have commenced the optimization phase in disease associated with NETosis. This collaboration is an addition to that announced last year with Werfen's Immunoassay Technology Center, a worldwide leader in specialized diagnostics. That agreement concerns another NETs-related disease, antiphospholipid syndrome, APS, and they too are making good progress. We believe that Volition's Nu.Q NETs test could provide not only improved diagnostic information to aid clinical decision-making and personalized care, but could also be a low-cost test to continue to monitor a patient's condition in many NETs-related diseases. Next up, Nu.Q Cancer, specifically Nu.Q Lung Cancer. Lung cancer is a major cause of cancer-related mortality worldwide. We believe that Nu.Q Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring. Research conducted by our long-term collaborators in Taiwan and Lyon in France demonstrated that our Nu.Q Cancer technology empowers clinicians to make more informed treatment decisions, and provides valuable new monitoring capabilities throughout the patient journey. Several manuscripts, conference posters, and presentations have already been published. Subsequent to quarter end, two further papers have been made available on preprint services with a further manuscript due for submission by the NTU team in the coming weeks. This evidence provides the basis of our reimbursement submission, supported by our long-term collaborators at Hospices Civils de Lyon, one of Europe's leading cancer centers. This reimbursement is the next step on the path to the first use of Nu.Q in clinical practice, an exciting prospect which is core to Volition's mission: using our tests to save lives. This quarter, we participated in our first pre-submission meeting with the authorities and anticipate a follow-up meeting and ultimately a submission by the third quarter of this year. Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q in the human cancer field. Assuming achievement, we anticipate the introduction into routine clinical use in France, and then we'll set our sights on rolling it out in other countries. Staying with cancer, but moving on to our Capture-Seq technology. Volition is, I believe, the first company to demonstrate the isolation analysis of greater than 99% pure circulating tumor-associated DNA. Most current liquid biopsy methods involve deep sequencing of plasma DNA and bioinformatic analysis of the data produced to identify the presence of cancer in a patient. The biggest problem facing all liquid biopsy methods worldwide is that the vast majority of the circulating DNA in blood plasma established from cancer patients comes from healthy cells, not from the cancer. Volition's technology employs an entirely novel approach to liquid biopsy that has overcome this hurdle and produces pure cancer-associated plasma DNA sequences set for liquid biopsy. Our clinical paper detailing this technology has been peer-reviewed and published subsequent to quarter end. The manuscript describes a new liquid biopsy chemistry for isolating CTCF DNA from plasma. Our work on CTCF bound DNA has revealed what we believe to be an unprecedented new discovery, that there is almost no CTCF bound DNA in healthy plasma, and almost all CTCF bound DNA in the blood of cancer patients is therefore derived from the cancer. In the published paper, we report a new two-step method for preparing pure circulating tumor DNA data sets for cancer patients. Firstly, through physical enrichment of the sample and secondly, through bioinformatic removal of virtually all background non-tumor cell-free DNA sequences from the DNA sequence data set. These methodological and biological breakthroughs represent a novel liquid biopsy method for a novel class of potentially thousands of liquid biopsy sequence biomarkers. Capture-Seq shows potential for both a multi-cancer early detection approach, either alone or in combination with other tests, and the detection of minimal residual disease, MRD. Our goal is to secure a wide range of licensing agreements in the human diagnostic space, mirroring our strategy in the vets market. We anticipate diverse deal structures with potential for upfront and milestone payments and future recurring revenue. We are in active discussions with several large liquid biopsy and diagnostic companies to accelerate the development of our Capture-Seq technology, and we are in the process of undertaking technical evaluations with potential licensors. We believe the potential use cases for Capture-Seq represent a significant commercial opportunity with a total addressable market on an annualized basis of approximately $23 billion for the human multi-cancer early detection use, and should it prove useful, over $13 billion for MRD use. From a Nu.Q Vet perspective, we made solid progress with our research into the use of Nu.Q in cats, most notably with our submission for peer review, our clinical manuscript. This paper reports the high accuracy of our Nu.Q Vet feline prototype assay in detecting lymphoma in cats, the most common cancer in the species. At 97% specificity, the assay detects 86% of feline lymphomas. This breakthrough marks the development of what we expect to be the world's first simple, affordable, blood-based liquid biopsy test for feline cancer, a significant unmet need in vet medicine. This opens up the potential for cancer screening and monitoring in cats. There are more than 60 million cats in the U.S. alone, 25% of which are senior cats, and thereby suitable for an annual check. We believe this represents a tremendous commercial opportunity for VolitionRx. The publication of this study in a peer-reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment. We also expect to generate ongoing revenue in this large and growing market where our technology meets an unmet need. We have made incredibly quick progress from a product development perspective, given it was only in May of last year that we reported detecting nucleosomes in cats, the third species for Nu.Q. With that, I'll pass over to Terig for our financial report. Thanks very much, Cameron, and hello everyone. I am delighted to provide a financial report for the second quarter ended 30th of June, 2026. After reporting first quarter revenue of approximately $1 million with year-on-year growth of approximately 300%, second quarter revenue performance was more subdued. We recorded approximately $0.4 million in the second quarter, broadly in line with approximately $0.4 million in the same period of 2025. This result reflected higher Nu.Q Vet revenue offset by lower services revenue from Nu.Q Discover, partly reflecting the timing and lumpy nature of project delivery. Taking the first half in total revenue was $1.4 million and year-on-year growth was 112%. As we have stated previously, at this early stage of commercialization, revenues remain fairly uneven and difficult to predict from one quarter to the next. While we remain confident of continuing to see solid growth year-over-year, we will not be providing revenue guidance for 2026 at this point in time. From an expenditure perspective, total operating expenses for the quarter were $4.6 million compared to $6.7 million in the same period last year, a 32% reduction year-on-year. This reflected savings from our cost reduction program, including a 27% reduction in headcount compared to the same point in 2025. As we reported in the 10-K, looking at the trend over the last two years, we now operate at significantly lower levels of expenditure. Furthermore, we have and will continue to take measures to reduce costs further in 2026. Net loss for the quarter was $7.3 million compared to $6.3 million in the same quarter in 2025. This increase was primarily due to non-cash accounting charges of approximately $3 million related to the Lind convertible notes, partially offset by the $2.1 million reduction in operating expenses noted above. Net cash used in operating activities for the quarter was $5.2 million, compared with $6.3 million in the comparable 2025 quarter, reflecting the partial impact of cost savings noted above. Cash and cash equivalents at the end of the quarter totaled approximately $2.8 million, compared to $1.1 million as at December 31, 2025. Receipts in the second quarter of 2026 included approximately $1.2 million in net proceeds from our at-the-market or ATM facility and approximately $4.1 million in net proceeds from a confidentially marketed public offering of shares and warrants through Maxim Group. To summarize the finance report, second quarter revenue was flat year-on-year, however, up 112% year-on-year for the first half of the year. Operating expenses for the second quarter were 32% lower year-on-year. Operating loss was 34% lower year-on-year for the second quarter, and we continue to work on reducing our underlying operating expenses. I will now pass over to Cameron for a look at what's to come in the second half of the year. Thank you, Terig. Looking ahead, we have a lot of exciting milestones. Starting with Nu.Q Vet, in addition to the anticipated publication of the feline paper, we also anticipate further development work of the assay as we prepare to commercialize the use of Nu.Q in cats. From a Capture-Seq point of view, we are fast-tracking its development, conducting further studies, including competing conditions and larger sample sets, and working with oncology key opinion leaders. We also anticipate additional publications and conference presentations in the coming months. Lastly, but certainly by no means least, we look forward to completing the ongoing and indeed proposed technical evaluations with potential licensing companies. For Nu.Q Lung Cancer, our laser focus is on gaining reimbursement status for the product in France. We also look forward to sharing emerging evidence about the use of Nu.Q in lung cancer in identifying minimal residual disease, sharing another clinical paper from the NTU team, and completing the final validation study with Hospices Civils de Lyon. So lots to look out for. Regarding Nu.Q NETs, our recent momentum will continue into the second half of the year and beyond. We are now actively targeting NGO partnerships and strategic collaborators with companies operating in low-income countries to accelerate the commercialization and market penetration of our breakthrough lateral flow assay. Working with Professor Djillali Annane and team, we look forward not only to finalizing the 1,000+ patient IHU study, but also starting the DetectSep program planned for September. As a reminder, DetectSep is a French government-sponsored real-world evaluation of early detection of sepsis, and Volition's Nu.Q NETs is the sole biomarker. The DetectSep program provides an opportunity to receive individualized or personalized care adjusted to the risk of deterioration and progression to sepsis. It is indeed a privilege to be involved in such a program, and we hope that through the early identification of sepsis, lives can be saved, the quality of life of survivors can be improved, and importantly, that the burden on the healthcare systems can be reduced. As a final note, to end on a high, I am also enormously proud to announce our continued work with the world-renowned Mayo Clinic in yet another potentially significant use of our Nu.Q NETs assay beyond sepsis. You may recall the publication of a study at the Mayo Clinic in the Shock Journal earlier this year. The Mayo Clinic study of 674 trauma patients demonstrated that the nucleosome levels, as measured by Volition's Nu.Q H3.1 and Nu.Q H3R8 Citrulline, are elevated in people that have experienced a traumatic event and are even higher in those patients that go on to have complications from the trauma. The numbers are quite stark indeed, and some of the most compelling data that I have seen. H3.1 levels in healthy people were an average of 22.3 ng /ml. Those with trauma were 359.7 ng/ml on average, and those that went on to get venous thromboembolism were 828.4 ng/ml, over 37x the level of healthies. The identification of reliable biomarkers in trauma patients is a clinical challenge and remains an unmet need in the emergency and surgical setting. I am absolutely delighted to confirm that we are now in the process of supplying the Mayo Clinic with an Immunodiagnostic Systems i10 automated analyzer, our established Nu.Q automated platform. As Professor Park, principal investigator and senior author of the paper, says, "A first step into getting the Nu.Q NETs product into the Mayo Clinic's laboratories." Dr. Park is an intensive care clinician and a translational researcher and is looking to develop a trauma patient model utilizing H3.1 at admission. She estimates their clinic sees approximately 2,200 trauma patients per year. She commented, "These biomarkers could aid in early risk identification and may inform targeted preventive strategies in trauma care." For my part, I believe this is a significant study with clear data, not only for clinicians, patients, and their families, but also for Volition. A peer-reviewed publication with the Mayo Clinic research team can only support our efforts to commercialize our Nu.Q NETs product. The IDS i10 should be placed within the Mayo Clinic this quarter, and we very much look forward to sharing further updates in the coming months. Finally, in drawing to a close, we have developed a truly remarkable, versatile platform and are working with governments, leading hospitals, KOLs, and some of the biggest diagnostic and liquid biopsy companies to make our technology available worldwide as quickly as possible. We set out 15 years ago to help save lives and improve outcomes for millions of patients worldwide, and we are making huge progress towards these goals. With the first clinical use now imminent in both early sepsis detection and lung cancer management, we are about to be part of the solution through simple, easy-to-use, low-cost tests. Our vision is for our technology to be incorporated into tests that will be used first by millions and ultimately hundreds of millions of people and animals a year with our platform licensed to a range of large diagnostic and liquid biopsy companies and governments worldwide. Combining what we believe to be groundbreaking technology with their installed base of laboratories, analyzing machines, and sales forces around the world will achieve the optimal outcome for us. Large companies have the resources to realize the opportunities better than VolitionRx does on its own. We anticipate that the total addressable markets, TAMs, for our technologies on an annualized basis are multibillion-dollar opportunities, not only for VolitionRx, but for our licensing partners too. VolitionRx has made strong progress both clinically and commercially. We are very active with a range of potential partners and are continuing our discussions with more than a dozen of the world's leading diagnostic and liquid biopsy companies to license and commercialize our very broad IP and product portfolio. These discussions are at various stages of the negotiation process across all our different pillars. Our laser focus is on executing licensing agreements, and we will update you as they progress. Thank you for joining the call today. We very much appreciate it. We will now take your questions. Operator? Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Our first question will come from Michael Okunewitch with Maxim Group. Hey, guys. Congrats on all the progress, and thanks so much for taking my questions today. Thank you. Just to start off, I wanted to ask about the lateral flow-based NETosis test. It is fairly impressive performance, it seems, compared to the venous draw. If I am interpreting correctly, it does seem like there is a little bit of a loss of diagnostic accuracy as would be expected for the format. My question is, how might this be applied versus the CE -marked central lab-based test? Yeah, very good question, Mike, and a very good one to go through. Ultimately, in America and a lot of places, the most common test will probably be a lab test. It is easy, part of your normal blood draw. It gives you the NETs numbers, and it goes off as part of the normal blood work. Very helpful. Things like CRP, which are hundreds of millions of tests per year worldwide in labs, and I think we could certainly be more helpful than that, so a huge market. But if you need a question answered very quickly, even a stat in the busiest hospital will take an hour. You can do a finger- prick test. Also in developing countries, it is extremely helpful where they have less infrastructure. As we talk about, could also be useful in things like Ebola. We talked about cytokine storms in a whole lot of areas. If you have a worried parent or someone who has a child that is sick, you can take it at home as a pin prick. I think it greatly expands the market. The correlation was 90%, and if you look at the numbers from trauma, for example, that is extremely helpful, and actually is incredibly close for two completely different formats. For example, I discussed the results for the trauma, the Mayo Clinic, amazing to be working with them. They really think this is a great test, not only where we think in sepsis and other things, but in trauma, which is, what, 40 million people a year are admitted for trauma in the U.S.? The numbers are quite stark, from 22 to 800. So a 90% correlation is obviously going to be very good in all those areas. I think that the point of care opens up. It does not, by any means, replace a lab. That is the easiest, quickest way for most people to have the test, but I think it opens up a lot of other aspects. And we are in discussions with groups to launch in developing countries, looking with large multinational organizations, and it is something which Volition could also keep a hold of. There is no way we are going to want to launch our own central lab test. That is done by Siemens and Roche and Abbott, that we do not want to compete with them. However, it is something we could contract, manufacture, and sell quite easily. Because they correlate so well, it means it will be much easier to get them regulatory approval once we have approval on the main platforms, as we have with Nu.Q NETs in Europe and the CE Mark on the Revvity machine. It just makes everything easier if the two tests agree so well. They are not exactly the same, but that is 90% correlation, although high 80s is extremely good and as good as you could expect. We are very excited. It opens up all the different markets for Nu.Q NETs. I think it is particularly important for take-home tests and for the developing world. And that was data which is incredibly encouraging, and we are hoping to have a lot more information on rolling that out, hopefully with large international organizations in the coming months. All right. Thank you. I appreciate the additional clarity on that. Just to follow up, the point-of-care lateral flow format, could this be a proof of concept and have potential for development in other areas like your Nu.Q Cancer test or some of the other nucleosome-based tests that you're doing? Absolutely. What we detect is H3.1, which is the basis for, obviously, the sepsis test. But in theory, everything we develop in either humans or cancer or NETosis sepsis is applicable in animals. It is applicable in all of our range of all the nucleosome assays. And we have got other assays for different things. It is certainly in concept extremely. For example, the test which has been launched by Antech in the vet market could absolutely be used in humans or a similar one in humans. Those little machines as well as lateral flow as well as the big machines. For example, the machine that the Japanese now have our vet test automated. That is on the Revvity i10 machine, which is the same as the human machine. And we are working on cats. There is every reason to believe it will also work on cats. Where H3.1 or other assays, immunoassays work in humans, in NET, in cancer, all of them should work in all the different use cases. And that shows yet again the amazing breadth of what we have developed. It all fits together very well. Thank you. Just one more from me before I hop back into the queue. I wanted to ask about the feline cancer diagnostic and specifically, how the lower level of specific breed in cats could impact that screening market, since it is not like dogs, where you can take specific breeds that are at greater risk of certain cancers, it is a much more general population with cats. Yeah. Very good question. We shorthand, people often say that the cat market is the same as the dog market in size or even bigger. That's a little optimistic because I don't know if you have a cat, but they can be a little more cantankerous, and they're not as inclined to go to the vet. So currently, there are a lot less money to be made or visits by cats than dogs to veterinary. But I think that's also what vet companies are trying to improve. Everyone's looking to broaden the market and make more useful tests for more animals. They're trying very hard to find reasons to bring cats into the vets and give them tests. As of today, there's absolutely no current market for any cancer test. There's no cancer test out there in the feline market. What we're starting with is absolutely the start. In lymphoma, the data was awesome. 97% specificity, 86% sensitivity. I mean, that's even better than a lot in dogs. That was with some very world-renowned vets in different countries collecting the samples. I don't think it's fair to say it will double market for the reasons you mentioned. Also, there are less cat visits, but it's such a large market. There are tens of millions of eligible cats around the world. It would potentially be a very lucrative market. They do tend to live longer than dogs, so there's a time period. It's all something we're working on, but I think any way which you slice and dice it's millions or tens of millions of tests per year is the TAM worldwide. As before, the cost of goods is very low, compared to what can be charged for it. It's a very high-margin product and a big need. In all our areas, the margins are very good and the process, but the exact size of the cat market, I guess we'll find out once the product's launched. But I would look at it as a smaller potential market than the dog market, but large nonetheless. All right. Thank you very much, Cameron. I really appreciate you taking my questions today. Thank you. Take care. Our next question will come from Justin Walsh with JonesTrading. Hi. Thanks for taking the question. It would be great if you could provide some additional color on the reimbursement approval process relevant to Nu.Q Lung Cancer in France. Any potential risk there and how that process compares to comparable processes in other regions? Yes. It is a different process, and there's always a risk in reimbursement. Nothing by any means is a fait accompli until it's done. But the French government have several programs now where they're trying to get encourage more tests to come on the market. We had our first pre-submission meeting a few weeks ago, and we're still very hopeful of getting this first level approved. It's a bit different from the system in the U.S., and there's quite a few complications. I can probably go through it all offline. But, several aspects to your question. We are very happy that we're in this process with the French government, and they'll allow us to collect a large amount of data, once the reimbursements are working in France and start helping people. But it is a different system to the U.S., so, I can go through. It's probably take a half an hour to go through it. I won't do on this call, but it's a different process. But it's something which we're very happy with how it's going. As I said, we had the pre-submission meeting, and we expect to have the first news on that later this year and be helping people in real life in France next year. Thanks for taking the question. Thank you. We'll go next to Yi Chen with H.C. Wainwright. Good morning. This is Katie on for Yi. Morning, Katie. Thinking about your revenue quarter-over-quarter, how much of the first half's growth was one time deferred revenue versus catch-up versus organic growth and ramp? What do you expect your underlying run rate growth trajectory to be? Terig, do you want to run through that question? Yeah, thanks, Katie. This is Terig Hughes. Yeah, it is a good question. In the quarter, we did have probably a 50/50 split between deferred revenue and an actual product revenue. That deferred revenue is coming from the Heska agreement. As we ship tests in the vet space, we recognize a portion of that revenue, and that is over the life of the agreement. Yeah, we would expect something similar, going forward through the balance of the year. Again, not providing guidance on individual lines, but we would expect a similar performance over the balance of the year. Does that answer your question? Yes. Sorry. Quick follow-up. Should we expect quarterly revenue to be inconsistent, or are we expecting it to smooth out over time? Are there specific deals coming up that change H2? At this stage, and that is why we are not giving guidance, it is particularly lumpy. We are not expecting it to smooth out anytime soon. Part of it is shipping of large orders. Part of it is Discover Services, which is dependent on project revenue being recognized. That is where you saw we had a fairly flat quarter this quarter, partly because of the timing of the project delivery in Discover Services. We do have a good pipeline of large projects, but we are subject to our partners' timelines to a certain extent in terms of how we recognize that. Again, we expect to see growth over the full year. It is difficult to say one quarter to the next, but I am confident that over the full year we will show growth. Great. Thank you. I appreciate it. Thank you. Our next question will come from Bruce Jackson with StoneX. Hi, good morning. Thanks for taking my questions. First, could we get an update on the projects that are ongoing in Taiwan? You want me to take that, Cam? I think Cam might have dropped off. Oh, he might have dropped off. I can take that, Bruce. It's Lou. Okay. In terms of Taiwan, I don't know if you recall, but they presented a poster at the NACLC in the U.S. in December and then also again at ELCC this March, and it was around prognostication. They've really been focused around this risk stratification for patients ahead of surgery. They've not completed the data analysis for the screening section yet of the study because they've been writing up the paper for the prognostication. This is really helping them. They're looking to introduce it into routine clinical practice now, really looking at the measurement of H3K27 ahead of surgery to help identify those patients that they need to follow up more closely. That paper should be submitted within the next couple of weeks, and we'll put it up on a preprint service so people can see. That's why we haven't yet reported the data on the screening study. Okay. Then, in terms of the feline milestone payment, what is your latest thinking on the timing of receiving that? Yeah. Shall I take that one? The paper has been submitted, as you know, and it is still going through the peer review process. We are waiting for reviewers' comments to come back. It is taking a little bit longer than we had hoped. But I think it is just a matter of time before that gets published and then that would complete our obligations in terms of the milestone. Okay, perfect. Thank you very much. Thank you. Yeah, Bruce. We'll go next to Steven Ralston with Zacks. Good morning and good afternoon. I appreciated the update from the SUMMIT program. Since the finger-prick sample roughly mirrors the accuracy of the Spearman and Pearson correlations, would clinical trials be required to prove the time to result benefit? In other words, what will be the regulatory pathway for this? I think the next steps on that program, as you know, it's a program that's funded by the Walloon Region, so we're working together with a team there over in Belgium. The next steps are, because this has definitely been like the technology and the feasibility stage. The next stage is that it'll then will make the assay into research use only status so that it goes through some more quality checks, et cetera. Then it will be tested again in three independent hospitals, for clinical validation. So that will then be the clinical validation stage that we hope to start in early 2027. And hi, I'm back. Sorry, my phone rang out. Yes, Steven, it's one of those things. When having things correlate very well makes the regulatory process much better for de novo in different countries, and obviously it's much easier if it agrees with what's currently approved in Europe and the process, as you said, with a very strong correlation. That's not to say that there's never going to be any more regulatory work for it, but it just makes it a lot easier if it agrees with the current tests which are in the lab tests. The gold standard will still be currently the Revvity machine, and we're working with other companies to get that done. But at the moment, it's encouraging from a whole lot of ways. It means our platforms are both very stable. They're both measuring the same thing. But as I discussed briefly with Mike from Maxim, the numbers are quite a huge difference when you're talking 37x a healthy level in the most extreme cases for thrombosis, for example. Both have worked extremely well. The short answer is there will still be regulatory work needed, but we're also looking to use it internationally. So, each one of those areas will have a slightly different path. But in a lot of different ways, having it correlate so well with our current Revvity machine, which is the gold standard, helps us tremendously in getting it out there. Does that make sense? Yes. Thank you. Looking at it a different way, management has successfully reduced the quarterly operating expenses from over $8 million per quarter back in 2023 to down to $5.2 million in the most recent quarter. You've relayed some anticipated milestones that could bolster the cash runway in the near term. You've already entered into some agreements that provide upfront cash payments and milestone payments. Have any of the discussions advanced to the level of co-developmental funding? Yeah. Obviously we've got to be a little careful because there is a lot of different discussions going, and they are confidential. I don't want to break any of the agreements we have. But the agreements, and this is a probably good chance just to review where we are with all the different people we're talking to, they come into several categories. There's the autoimmune agreements, which are with two multi-billion dollar companies, Werfen and Sysmex, and as you said, they've progressed very well and they're progressing through the stages of co-development. They're working on their machines, and now we're working through the next phases. We have a deal with Revvity, which is obviously their machine, and they're co-marketing our CE Mark kits to dozens of hospitals, in Europe. It's a CE Mark kit they're selling. That's progressing well, and we're looking for a bigger agreement with them, and that's progressing well. We have an agreement with Hologic to help co-market our Nu.Q Discover. As you probably know, Hologic, they're a very large company as well. We're in discussion with several very large diagnostic companies on our Nu.Q NETs, beyond autoimmune and those other ones which we've already signed. As you can see, the data is looking better and better, with the Mayo Clinic, also with the large French DetectSep starting collection next month. Also, we're expecting data from a very large study called RECORDS as well, which was over a thousand also in France. They're progressing, but they were waiting for some of this bigger data, but that's certainly starting to come through, so hopeful of moving them along. There's a handful, actually more in the cancer space, on the Capture-Seq side, and some of the evaluation work is well and truly worked through. There's a range of other things we're licensing, but we'll go through that later. Also there's all the commercialization, which is working on lung prognostic in Taiwan, in Lyon, and also, actually, we're going through some other stuff which is progressing very well in Japan as well. So lots of different areas, and they're all at different stages and processes. I guess like everyone wants it to go as quick as it possibly can because that's what's going to get us out the other side of all the things going on and actually licensed. We currently have four agreements signed with multi-billion dollar companies, Werfen and Sysmex, Revvity and Hologic, and we're working on over a dozen others in those three main areas and governments and large companies. The secret to unlocking all that is more information on the human cancer side, which we're getting valuations for the Capture-Seq as well as H3K27. All the Nu.Q NETs work, in trauma and sepsis. As you heard, we're progressing very well with the Mayo Clinic, and an i10 has now been put in their lab, so they can do a lot more work, and we're hopeful of them becoming a customer in a sense of running the test for us as well, commercially. So yeah, everyone wants to be quicker, of course, including us, but there's been a lot of progress on all those different fronts. Does that help answer your question as much as I can? Yes. Thank you for the very meaty explanation of your pipeline here in the near future. Thank you. Excellent. Thank you. We will go next to Ilya Zubkov with Freedom Capital Markets. Good afternoon, and thank you for taking the question. Good afternoon. I have just a quick one, because Discover service revenue was 0 in Q2, and you said it was because of project delivery timing. I am just wondering, were these projects expected in Q2 simply pushed into Q3, or has there been any change in the underlying size or conversion rate of Discovery pipeline? Terig, do you want to answer that? Yep. Hi, this is Terig. It is not that they were necessarily expected in Q2, but, as I have said, it is always a challenge to predict when some of these projects will start. We are dependent on the timelines of our partners when they start clinical trials or other projects, so that we can then deliver those and recognize the revenue. That uncertainty does not change over the next couple of quarters. But like I said, we do have a pipeline of projects, and so it would be expected that some of those will drop, but it is very difficult to predict which ones will start in which quarters. Does that answer the question? Yeah. Thank you very much. And that concludes our question and answer session. I would like to turn the floor back over to Cameron Reynolds for closing comments. Thank you all for joining us today. Thank you for the analysts for all those great questions. I hope it has been helpful in outlining where we are going and the progress we are making on all the areas we are doing, and that we are very much focused on getting some of these deals. We have progressed four multi-billion dollar companies, as we talked about, but we are working on a lot of other and potentially much larger deals, and we hope to update you in short and medium term with how they are all going and some of them being completed. Thank you for your time and take care. Ladies and gentlemen, thank you for your participation. This does conclude today's teleconference. You may disconnect your lines and have a great day.